North China Pharmaceutical Huakun Hebei Biotechnology

North China Pharmaceutical Huakun Hebei Biotechnology is a specialized subsidiary of the North China Pharmaceutical Group (NCPC), one of China's largest pharmaceutical manufacturers. The company focuses on the research, development, and industrialization of advanced biopharmaceuticals, particularly recombinant proteins and monoclonal antibodies. It is most distinguished for developing Ormutivimab, the first domestically produced recombinant human anti-rabies virus monoclonal antibody approved in China. Operating out of Shijiazhuang, Hebei, the firm maintains state-of-the-art GMP manufacturing facilities that support large-scale production of high-value biologics. Huakun plays a pivotal role in NCPC's strategic transition from traditional antibiotic production to the high-growth biotechnology sector.